Lerodalcibep在心血管疾病患者或高危人群中的疗效与安全性:一项随机临床试验
这项随机双盲安慰剂对照3期试验在922例已接受最大耐受他汀治疗但LDL-C未达标的CVD或高危患者中评估lerodalcibep(每月300mg皮下注射)。52周时安慰剂校正的LDL-C降幅为56.2%(mITT),90%的lerodalcibep组患者同时达到LDL-C降低≥50%和指南推荐目标,安全性总体与安慰剂相似,仅注射部位反应更常见。
要点
- lerodalcibep每月300mg皮下注射52周,mITT分析安慰剂校正LDL-C降幅56.2%。
- 90%(555/615)的lerodalcibep组患者达到LDL-C降低≥50%且达指南目标。
- 安全性总体与安慰剂相似,注射部位反应6.9% vs 0.3%,多为轻中度。
核心结论
- 在CVD或高危患者中,lerodalcibep每月皮下注射显著降低LDL-C,安全性类似安慰剂。
- 结果支持对最大耐受他汀治疗仍LDL-C不达标者长期使用lerodalcibep。
研究设计与样本
- 随机、双盲、安慰剂对照3期试验,在11个国家66家诊所开展。
- 共随机922例患者(lerodalcibep组与安慰剂组2:1),811例(88%)完成试验。
- 纳入≥18岁、接受最大耐受他汀治疗且LDL-C≥70 mg/dL(CVD)或≥100 mg/dL(高危)者。
主要发现
- mITT分析安慰剂校正LDL-C降幅:第52周56.2%(SE 2.2%),第50与52周均值62.7%(SE 1.9%),均P<.001。
- ITT插补分析降幅:第52周49.7%(SE 2.4%),第50与52周均值55.3%(SE 2.2%)。
- 符合方案分析降幅:第52周60.3%(SE 2.3%),第50与52周均值65.9%(SE 1.9%)。
- lerodalcibep组555/615例(90%)达到LDL-C降低≥50%且达指南推荐目标。
- 治疗中出现的不良事件与安慰剂相似,注射部位反应lerodalcibep组42/613(6.9%)vs 安慰剂组1/307(0.3%),多为轻中度。
关键数值与推荐
- LDL-C降幅为主要疗效终点,采用百分比变化和50/52周均值评估。
- 指南推荐LDL-C目标达成与LDL-C降低≥50%共同作为达标指标。
临床怎么用
- 对于最大耐受他汀治疗仍LDL-C不达标的CVD或高危患者,可考虑加用lerodalcibep。
- 每月一次皮下注射,室温稳定,使用便利。
- 需关注注射部位反应,但多为轻中度且不增加停药率。
局限性
- 原文未报告长期心血管结局数据。
- 抗药抗体检测为体外 sporadic 阳性,未影响疗效,但需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recent changes in national and international lipid guidelines for reducing cardiovascular events recommend additional drugs, greater reductions, and lower targets for low-density lipoprotein cholesterol (LDL-C) if not attained with statins. The achievement of these targets with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has not yet been evaluated in a randomized clinical trial. OBJECTIVE: To evaluate the 52-week safety and efficacy of lerodalcibep, a small anti-PCSK9-binding protein, in patients with cardiovascular disease (CVD) or who are at very high or high risk of CVD and requiring addition LDL-C-lowering treatment. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized, double-blind, placebo-controlled phase 3 trial. The trial was conducted at 66 clinics in 11 countries between April 23, 2021, and November 15, 2023. Individuals 18 years and older taking maximally tolerated statin therapy with LDL-C of 70 mg/dL or greater with CVD or 100 mg/dL or greater if at high risk of CVD were included. INTERVENTIONS: Patients were randomized 2:1 to monthly 1.2-mL subcutaneous lerodalcibep, 300 mg, or placebo for 52 weeks. MAIN OUTCOMES AND MEASURES: The safety analysis included all randomized patients. The co-primary efficacy end points were percent change from baseline in LDL-C at week 52 and the mean of weeks 50 and 52. Secondary efficacy outcomes included additional lipid apolipoprotein measures and achievement of guideline-recommended LDL-C targets. RESULTS: Of 922 randomized participants (mean [range] age, 64.5 [27-87] years; 414 [44.9%] female; mean [SD] baseline LDL-C, 116.2 [43.5] mg/dL), 811 (88%) completed the trial. The mean (SE) placebo-adjusted reduction in LDL-C with lerodalcibep by modified intention-to-treat (mITT) analysis was 56.2% (2.2%) at week 52 and 62.7% (1.9%) for the mean of weeks 50 and 52; 49.7% (2.4%) and 55.3% (2.2%) by ITT with imputation using a washout model, and 60.3% (2.3%) and 65.9% (1.9%) by per-protocol analysis at week 52 and the mean of weeks 50 and 52, respectively (P < .001 for all). With lerodalcibep, 555 of 615 participants (90%) achieved both a reduction in LDL-C of 50% or greater and recommended LDL-C targets during the study. Treatment-emergent adverse events were similar between lerodalcibep and placebo, except for injection site reactions. These occurred in 42 of 613 participants receiving lerodalcibep (6.9%) compared to 1 of 307 receiving placebo (0.3%), were graded mild or moderate, and did not result in higher discontinuation of treatment, at 26 of 613 (4.2%) and 14 of 307 (4.6%), respectively. Sporadic in vitro antidrug antibodies were detected, which had no impact on free PCSK9 or LDL-C-lowering efficacy. CONCLUSIONS AND RELEVANCE: In this trial, lerodalcibep, a novel anti-PCSK9 small binding protein, dosed monthly and stable at ambient temperatures significantly reduced LDL-C in patients with CVD or at high risk of atherosclerotic cardiovascular disease with a safety profile similar to placebo. These results support long-term use of lerodalcibep in patients with CVD or at high risk of CVD who are unable to achieve adequate LDL-C reduction while receiving maximal tolerated statins alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04806893.
引用
- Klug EQ, Llerena S, Burgess LJ, et al. Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 38958989. doi:10.1001/jamacardio.2024.1659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。